Qianzhi Wang
Changsha, 410013, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 22, 2025
Sugemalimab for Post-PD-1 Progression in Non-small Cell Lung Cancer.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: July 08, 2025
Potential biomarkers of primary resistance to first- and second-generation EGFR-TKIs in non-small-cell lung cancer: a real-world study.
Journal: Therapeutic advances in medical oncology
Published: December 08, 2024
Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials.
Journal: Advances in therapy
Published: October 31, 2024
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 15, 2024
Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study.
Journal: EClinicalMedicine
Published: October 13, 2023
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.
Journal: British journal of cancer
Published: April 10, 2023
Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
Journal: Cancer medicine
Published: October 03, 2022
The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.
Journal: Translational lung cancer research
Published: July 16, 2022
Case Report: Tissue Origin Identification for Cancer of Unknown Primary: Gene Expression Profiling Approach.
Journal: Frontiers in oncology
Published: April 30, 2021
Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy.
Journal: Frontiers in oncology
Published: December 23, 2019
miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9.
Journal: Oncology letters
Published: January 05, 2015
Showing 1-12 of 12
Last Updated: 09/26/2026